TNXP Relative Valuation
TNXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNXP is overvalued; if below, it's undervalued.
Historical Valuation
Tonix Pharmaceuticals Holding Corp (TNXP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.31. The fair price of Tonix Pharmaceuticals Holding Corp (TNXP) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：19.88
Fair
-1.77
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Tonix Pharmaceuticals Holding Corp. (TNXP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.99. The thresholds are as follows: Strongly Undervalued below -17.45, Undervalued between -17.45 and -9.72, Fairly Valued between 5.74 and -9.72, Overvalued between 5.74 and 13.48, and Strongly Overvalued above 13.48. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.17
EV/EBIT
Tonix Pharmaceuticals Holding Corp. (TNXP) has a current EV/EBIT of -0.17. The 5-year average EV/EBIT is -0.37. The thresholds are as follows: Strongly Undervalued below -2.79, Undervalued between -2.79 and -1.58, Fairly Valued between 0.84 and -1.58, Overvalued between 0.84 and 2.05, and Strongly Overvalued above 2.05. The current Forward EV/EBIT of -0.17 falls within the Historic Trend Line -Fairly Valued range.
1.75
PS
Tonix Pharmaceuticals Holding Corp. (TNXP) has a current PS of 1.75. The 5-year average PS is 1.64. The thresholds are as follows: Strongly Undervalued below -3.32, Undervalued between -3.32 and -0.84, Fairly Valued between 4.12 and -0.84, Overvalued between 4.12 and 6.59, and Strongly Overvalued above 6.59. The current Forward PS of 1.75 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Tonix Pharmaceuticals Holding Corp. (TNXP) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.81. The thresholds are as follows: Strongly Undervalued below -27.29, Undervalued between -27.29 and -15.05, Fairly Valued between 9.44 and -15.05, Overvalued between 9.44 and 21.68, and Strongly Overvalued above 21.68. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Tonix Pharmaceuticals Holding Corp. (TNXP) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.70. The thresholds are as follows: Strongly Undervalued below -23.50, Undervalued between -23.50 and -12.60, Fairly Valued between 9.21 and -12.60, Overvalued between 9.21 and 20.11, and Strongly Overvalued above 20.11. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Tonix Pharmaceuticals Holding Corp (TNXP) has a current Price-to-Book (P/B) ratio of 0.78. Compared to its 3-year average P/B ratio of 0.41 , the current P/B ratio is approximately 90.96% higher. Relative to its 5-year average P/B ratio of 0.69, the current P/B ratio is about 13.45% higher. Tonix Pharmaceuticals Holding Corp (TNXP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -478.47%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -351.72% , the current FCF yield is about -100.00% lower.
0.86
P/B
Median3y
0.41
Median5y
0.69
-36.45
FCF Yield
Median3y
-478.47
Median5y
-351.72
Competitors Valuation Multiple
The average P/S ratio for TNXP's competitors is 0.00, providing a benchmark for relative valuation. Tonix Pharmaceuticals Holding Corp Corp (TNXP) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 16.58%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TNXP decreased by 40.78% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -503.65 to -972.95.
The secondary factor is the Revenue Growth, contributed 16.58%to the performance.
Overall, the performance of TNXP in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Tonix Pharmaceuticals Holding Corp (TNXP) currently overvalued or undervalued?
What is Tonix Pharmaceuticals Holding Corp (TNXP) fair value?
How does TNXP's valuation metrics compare to the industry average?
What is the current P/B ratio for Tonix Pharmaceuticals Holding Corp (TNXP) as of Dec 05 2025?
What is the current FCF Yield for Tonix Pharmaceuticals Holding Corp (TNXP) as of Dec 05 2025?
What is the current Forward P/E ratio for Tonix Pharmaceuticals Holding Corp (TNXP) as of Dec 05 2025?